These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Genotypic and clinical analysis of 49 Chinese children with hepatic glycogen storage diseases. Liang Y; Du C; Wei H; Zhang C; Zhang M; Hu M; Fang F; Luo X Mol Genet Genomic Med; 2020 Oct; 8(10):e1444. PubMed ID: 32772503 [TBL] [Abstract][Full Text] [Related]
3. The prevalence of polycystic ovaries in the hepatic glycogen storage diseases: its association with hyperinsulinism. Lee PJ; Patel A; Hindmarsh PC; Mowat AP; Leonard JV Clin Endocrinol (Oxf); 1995 Jun; 42(6):601-6. PubMed ID: 7634500 [TBL] [Abstract][Full Text] [Related]
4. Rapid ultraperformance liquid chromatography-tandem mass spectrometry assay for a characteristic glycogen-derived tetrasaccharide in Pompe disease and other glycogen storage diseases. Sluiter W; van den Bosch JC; Goudriaan DA; van Gelder CM; de Vries JM; Huijmans JG; Reuser AJ; van der Ploeg AT; Ruijter GJ Clin Chem; 2012 Jul; 58(7):1139-47. PubMed ID: 22623745 [TBL] [Abstract][Full Text] [Related]
7. A monocentric pilot study of an antioxidative defense and hsCRP in pediatric patients with glycogen storage disease type IA and III. Kalkan Ucar S; Coker M; Sözmen E; Goksen Simsek D; Darcan S Nutr Metab Cardiovasc Dis; 2009 Jul; 19(6):383-90. PubMed ID: 19073362 [TBL] [Abstract][Full Text] [Related]
8. Neurological Characteristics of Pediatric Glycogen Storage Disease. Muzetti JH; do Valle DA; Santos MLSF; Telles BA; Cordeiro ML Front Endocrinol (Lausanne); 2021; 12():685272. PubMed ID: 34093448 [TBL] [Abstract][Full Text] [Related]
10. A Liver-Specific Thyromimetic, VK2809, Decreases Hepatosteatosis in Glycogen Storage Disease Type Ia. Zhou J; Waskowicz LR; Lim A; Liao XH; Lian B; Masamune H; Refetoff S; Tran B; Koeberl DD; Yen PM Thyroid; 2019 Aug; 29(8):1158-1167. PubMed ID: 31337282 [No Abstract] [Full Text] [Related]
11. Development of minimally invasive Turki A; Stockler S; Sirrs S; Salvarinova R; Ho G; Branov J; Rosen-Heath A; Bosdet T; Elango R Mol Genet Metab Rep; 2022 Jun; 31():100880. PubMed ID: 35585965 [TBL] [Abstract][Full Text] [Related]
12. An association among iron, copper, zinc, and selenium, and antioxidative status in dyslipidemic pediatric patients with glycogen storage disease types IA and III. Kalkan Ucar S; Coker M; Sözmen E; Goksen Simsek D; Darcan S J Trace Elem Med Biol; 2010 Jan; 24(1):42-5. PubMed ID: 20122579 [TBL] [Abstract][Full Text] [Related]
13. Modifiable factors affecting renal preservation in type I glycogen storage disease after liver transplantation: a single-center propensity-match cohort study. Chan YC; Liu KM; Chen CL; Ong AD; Lin CC; Yong CC; Tsai PC; Lu LS; Wu JY Orphanet J Rare Dis; 2021 Oct; 16(1):423. PubMed ID: 34635148 [TBL] [Abstract][Full Text] [Related]
18. Amino acid disturbances in type III glycogenosis: differences from type I glycogenosis. Slonim AE; Coleman RA; Moses S; Bashan N; Shipp E; Mushlin P Metabolism; 1983 Jan; 32(1):70-4. PubMed ID: 6336817 [TBL] [Abstract][Full Text] [Related]
19. Serum lipid and lipoprotein profile of patients with glycogen storage disease types I, III and IX. Geberhiwot T; Alger S; McKiernan P; Packard C; Caslake M; Elias E; Cramb R J Inherit Metab Dis; 2007 Jun; 30(3):406. PubMed ID: 17407002 [TBL] [Abstract][Full Text] [Related]